Navigation Links
Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
Date:6/30/2008

- Product appears safe with no dose-limiting toxicities -

- Chemophase dose for pivotal trials successfully determined - - Halozyme to seek input from regulatory authorities in order to advance

into pivotal clinical program in 2009 -

SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a status update for its continuing Phase I/IIa Chemophase(R) clinical trial in the treatment of superficial bladder cancer. Based on the results, the Chemophase combination treatment of mitomycin plus the recombinant human hyaluronidase (rHuPH20) enzyme was well tolerated and appears safe. The study reported no dose-limiting toxicities and no observed side effects attributable to the enzyme, and established the dose for subsequent clinical trials, therefore achieving the pre-defined primary objective of the study. In addition, there were no neutralizing antibodies to rHuPH20 detected and the plasma concentration of mitomycin was either non-measureable or negligible and well below the threshold that may be predictive for myelosuppression (a decrease in bone marrow activity, resulting in fewer red blood cells, white blood cells, and platelets).

The study also provided support for future pivotal trial development that will incorporate the highest combination dose studied in the current trial, mitomycin plus 800,000 Units of rHuPH20. Commenting on the results, Richard C. Yocum, M.D., Vice President of Clinical Development and Medical Affairs at Halozyme stated, "We are pleased the study demonstrated that Chemophase was well-tolerated and produced no dose-limi
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
2. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
5. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
6. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
7. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
8. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
9. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...CATAWAY, N.J., Nov. 9 Mi..., the recognized leader in computer-controlled inj...be showcasing its patented, award-winning STA Sin... the Madow Group,s 15th year of TBSE titled "The L...the Las Vegas Hilton. ,, The STA System is ...
(Date:11/9/2009)...NCETON JUNCTION, N.J., Nov. 9 Unwa...dical devices, but recognizing today,s economic cl... quality aesthetic laser systems, introduces the M...riced at under $50,000. ,, The MOSAIC CO2 offe...ional technology including scanning and stamping o...
(Date:11/9/2009)... ARBOR, Mich., Nov. 9 Thomson Re...al Xpert(TM) CareFocus, a leading clinical surveil...at-risk patients in real-time and respond immediat...ost of treatment. ,, This upgrade is available ...st. ,, CareFocus 2.0 contains several powerfu...
Breaking Medicine Technology:Milestone Scientific to Exhibit at the 15th Anniversary of TBSE (The Best Seminar Ever) in Las Vegas 2Lutronic(R) Unleashes the New MOSAIC CO2 2Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 2Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 3K State geographer working to clarify what sustainability really means to rural decision makers 10035 1K State geographer working to clarify what sustainability really means to rural decision makers 10035 2Rutgers to collaborate in 243 4 million effort to improve prostate cancer identification using MRI 10032 1Rutgers to collaborate in 243 4 million effort to improve prostate cancer identification using MRI 10032 2Northern brown bears discovered feeding on whitefish runs 10029 1Northern brown bears discovered feeding on whitefish runs 10029 2
... an upcoming issue of,Anti-Cancer Drugs , VANCOUVE...TSX-V:PRX) today announced that two peer-reviewed ...urnal of the National Cancer,Institute ("JNCI") ha... and his team at Johns Hopkins University in colla...es the Company,s compound,PRX302, which is a pros...
...expressed protein,protects human pancreatic cancer...oving one of the body,s natural defenses against,o...ersity of Texas,M. D. Anderson Cancer Center repor... , The protein tissue transglutaminase, known by t...researchers at M. D. Anderson and,elsewhere to be ...
Other Medicine Technology:Protox Announces Publication in Journal of the National Cancer,Institute Supporting PRX302 as Treatment for Prostatic Diseases 2Protox Announces Publication in Journal of the National Cancer,Institute Supporting PRX302 as Treatment for Prostatic Diseases 3Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 2Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 3
(Date:11/9/2009)...le have tried to read Charles Darwin,s "Origin of ...nniversary this month, but gave up. , For them a...about, help by way of a new book is at hand. , W...k is the author of "The Origin Then and Now: A...(Princeton University Press, 2009), which makes Da...
(Date:11/9/2009)..., but not all agree , , MONDAY, Nov. 9 (...olution might have soothing short-term benefits, b...ions in the long run by stripping your nose of cri...we are removing the bad mucus but, unfortunately, ...the antimicrobial agents as well," said Dr. Talal ...
(Date:11/9/2009)...quo;s Today Show featured a return of the Berns Tr...day Nov. 6th 2009, The segment followed up with C...pearance on the Today Show on May 28th 2009 in whi...heir treatments by Dr. Jill Waibel of Miami, FL wi... (PRWEB) November 9, 2009 -- N...
(Date:11/9/2009)...ver Career College launches month-long clothing dr..., BC (Vocus) November 9, 2009 -- The students and ...gging through their closets to find clothing to. N...same in order to help women and children in need.,...ommunity here on campus amongst our students, staf...
(Date:11/9/2009)...wire-USNewswire/ --- The U.S. Centers for Disease ...Pennsylvania Coalition Against Rape $1.5 million d...g its National Sexual Violence Resource Center (NS...00 to serve as the nation,s principle center for c...formation and resources about all forms of sexual ...
Breaking Medicine News(10 mins):Health News:Book by UC Riverside biologist explains Darwin's 'Origin of Species' 2Health News:Sinus Rinses May Do More Harm Than Good 2Health News:Sinus Rinses May Do More Harm Than Good 3Health News:Lumenis Ultrapulse TotalFX Featured for the Treatment of Burn Scars on the Today Show 2Health News:Lumenis Ultrapulse TotalFX Featured for the Treatment of Burn Scars on the Today Show 3Health News:Lumenis Ultrapulse TotalFX Featured for the Treatment of Burn Scars on the Today Show 4Health News:Surrey College Students Collect Clothing for Women and Children 2Health News:CDC Awards Vital Prevention Funding to National Sexual Violence Resource Center 2
...BME (BioMedical Enterprises,Inc.), a privately hel...,shape memory implant technology, today announced ...tinol implant designed for internal fixation of,bo...aple changes shape when heated above body temperat...
...sland research is turning conventional wisdom on i... , Professor Bill von Hippel, from UQ,s School o... people,s age and their social satisfaction and he...Hippel measured social activities and social satis...
...ol of risk factors, less likely to get cholesterol...Day News) -- Women with type 2 diabetes and heart ...t they need than men, making their ability to cont...in San Francisco, probably explains why death from...
...June 16 NightHawk,Radiology Holdings, Inc. (Nasda...tions to radiology groups and hospitals throughout... results of its modified Dutch auction,tender offe...hares were properly tendered and not withdrawn at ...
... June 16 Cardiva Medical, Inc., a,privately held ...ang,Catalyst(TM) System announces that it will pre...atalyst(TM) II System and completion of its US,sal...technology investment and partnering conference he...
...pers Get a Campaign Bandana, Dog Owners Get an O...other Diseases, DENVER, June 16 Camp Bow Wow, th...vernight camp, has launched a fund raising,effort ...eases. Beginning June 16 at 26 Camp Bow Wow,locati...
Other Medicine News:Health News:BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the Barbed OSStaple(TM) (BOSS) Nitinol Implant 2Health News:Less Intensive Treatment Given Diabetic Women With Heart Disease 2Health News:NightHawk Radiology Holdings, Inc. Announces Preliminary Results of Its Tender Offer; NightHawk Expects to Purchase 2,367,438 Shares of Its Common Stock at $8.05 per Share 2Health News:NightHawk Radiology Holdings, Inc. Announces Preliminary Results of Its Tender Offer; NightHawk Expects to Purchase 2,367,438 Shares of Its Common Stock at $8.05 per Share 3Health News:Cardiva Medical, Inc. to Present at the 'Investment In Innovation (In3) Medical Device Summit' on June 18, 2008 in San Francisco, CA; Announces the Completion of Its Latest Phase in Its US Sales Force Expansion 2Health News:Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundation's Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in Minnesota Participating 2
...offered as 1-piece or modular, in regular or extra...omized with handles of choice and other options su...tandard patterns are available from Mediflex stock...s. , Please Note: Individual instrument componen...
...offered as 1-piece or modular, in regular or extra...omized with handles of choice and other options su...tandard patterns are available from Mediflex stock...s. , Please Note: Individual instrument componen...
...offered as 1-piece or modular, in regular or extra...omized with handles of choice and other options su...tandard patterns are available from Mediflex stock...s. , Please Note: Individual instrument componen...
...offered as 1-piece or modular, in regular or extra...omized with handles of choice and other options su...tandard patterns are available from Mediflex stock...s. , Please Note: Individual instrument componen...
Medicine Products: